aviditybiosciences.com - RNA Company Value to Revenue

aviditybiosciences.com (RNA) - corporate logo

Attracting top biologists through stock options stimulates the development of Avidity Biosciences (RNA), which impacts the company's enterprise value-to-revenue ratio. This -2090.42 indicator expresses the current value of the metric. Business stability relies on independence from macro cycles, while strict patents and FDA oversight guarantee long-term protection, creating high barriers to entry for new industry players.

RNA Avidity Biosciences, Inc.: EV/Sales Multiple in the range 11/23/2025 - 11/20/2026

Avidity Corp - analytical breakdowns and key metrics (RNA)

- issuer market value details:
Fundamental company valuation:RNA, aviditybiosciences.com
Finished products of Avidity

Leveraging a unique biotech patent portfolio, Avidity Biosciences (RNA) aims to secure market leadership and high margins. By analyzing EV/Sales dynamics, an investor assesses the business value including net debt relative to revenue, which helps identify whether the asset is overbought or if there are hidden solvency risks in the event of declining sales, regardless of the company's financing structure.

Competitor analysis

TEM (tempus.com) - Company Value to Revenue Ratio|qiagen.com (QGEN) - Enterprise Value-to-Revenue Ratio|Ionis (IONS) - EV/Sales Multiple|Enterprise Value-to-Revenue Ratio Repligen|CRISPR Therapeutics Corp - Enterprise Value to Sales Volume|Enterprise Value-to-Revenue Ratio genedx.com (WGS)|EV/Sales Multiple ultragenyx.com (RARE)|EV/Sales Multiple BEAM (Beam Therapeutics Inc)|Sarepta Therapeutics Inc (SRPT) - Enterprise Value-to-Revenue Multiple|twistbioscience.com - EV/Sales Multiple|10x Genomics, Inc. - Enterprise Value-to-Revenue Coefficient|NTLA (Intellia Corp) - Company Value to Revenue|Company Value to Revenue stoketherapeutics.com|Company Value to Revenue BLFS|Company Value to Revenue Wave Life Sciences Corp (WVE)|EV/Sales Multiple MAZE|Total Company Value-to-Revenue Ratio Sionna Therapeutics Inc|Enterprise Value-to-Revenue Ratio Prime Medicine Corp PRME|tayshagtx.com (TSHA) - Enterprise Value-to-Revenue Multiple|QURE - Enterprise Value-to-Revenue Ratio|MeiraGTx Holdings (MGTX) - Company Value to Revenue|Regenxbio (RGNX) - Enterprise Value-to-Revenue Ratio|SLDB - Total Company Value-to-Revenue Ratio|OCGN (Ocugen Inc) - EV/Sales Multiple|Enterprise Value-to-Revenue Ratio PACB|Enterprise Value-to-Revenue Ratio Benitec (BNTC)|Design Therapeutics Inc - Company Value to Revenue Ratio|Enterprise Value-to-Revenue Ratio Rocket Pharma RCKT|EV/Sales Multiple 4DMT FDMT|LXEO - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Korro Bio Inc.|EDIT: EV/Sales Multiple|SLN - Total Company Value-to-Revenue Ratio|PRQR (ProQR Therapeutics) - EV/Sales Multiple|codexis.com (CDXS) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple SGMO|EV/Sales Multiple Nautilus Biotechnology, Inc. (NAUT)|EV/Sales Multiple MGX (Metagenomi Inc.)|Business Value to Revenue DTIL|Generation Bio Co. - EV/Sales Multiple|BOLD: Enterprise Value-to-Revenue Ratio|XCUR (Exicure, Inc.) - Company Value to Revenue|Company Value to Revenue Ratio IMNN|Enterprise Value-to-Revenue Ratio RXi Pharmaceuticals|mustangbio.com (MBIO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio TransCode (RNAZ)|Bionano Genomics Inc. - Company Value to Revenue Ratio|Applied DNA Sciences - Company Value to Revenue|Total Company Value-to-Revenue Ratio bluebirdbio.com (BLUE)|IPA - Enterprise Value-to-Revenue Ratio|OMGA - EV/Sales Multiple|OMIC (Singular Genomics Systems, Inc.) - Company Value to Revenue|Regulus Therapeutics Inc - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Syros Pharmaceuticals|Company Value to Revenue Telesis Bio (TBIO)|EV/Sales Multiple TCON|UBX - Enterprise Value-to-Revenue Multiple